Comparison of Thrice-daily Novomix Insulin Versus Insulin Glargine Once-Daily Combined with Thrice-Daily Insulin Aspart on Glycemic Control in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Study

Mirtorabi, Seyyed Hossein; Razavi, Roghaye; Mirjalili, Roghaye; Namiranian, Nasim; Modarresi, Mozhgan; Azizi, Reyhaneh

Volume 16, Issue 3 (8-2024) IJDO 2024, 16(3): 149-153 | Back to browse issues page

Mendeley

Zotero

RefWorks

Mirtorabi S H, Razavi R, Mirjalili R, Namiranian N, Modarresi M, Azizi R. Comparison of Thrice-daily Novomix Insulin Versus Insulin Glargine Once-Daily Combined with Thrice-Daily Insulin Aspart on Glycemic Control in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Study. IJDO 2024; 16 (3) :149-153
URL: http://ijdo.ssu.ac.ir/article-1-884-en.html

Comparison of Thrice-daily Novomix Insulin Versus Insulin Glargine Once-Daily Combined with Thrice-Daily Insulin Aspart on Glycemic Control in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Study

Seyyed Hossein Mirtorabi

, Reyhaneh Azizi ^*

Assistant Professor of endocrinology, Yazd Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

Abstract: (244 Views)

Objective: The objective of the present analysis was to compare the effect of these two treatment regimens (Novomix insulin twice or thrice-daily versus once-daily insulin glargine plus twice or thrice-daily insulin aspart) on glycemic control in Iranian patients with T2DM.
Materials and Methods: This cross-sectional study was conducted for one year on people with type 2 diabetes referred to Yazd Medical Research Center. Glycemic control (HbA1C, FBG, and 2hPP) from baseline (week 0) to 24 -48 weeks were recorded in the electronic file of patients receiving Novomix insulin twice or thrice daily. These profiles were compared to those of patients receiving once-daily insulin glargine plus twice or thrice-daily insulin aspart (according to each meal). P< 0.05 was considered as a significant level.
Results: Based on the finding, both treatment groups demonstrated significant reductions in FBG, 2hPP, and HbA1c from baseline to the study endpoint (weeks 24 and 48) (P< 0.05 for all comparisons). However, the changes in HbA1c, FBG, and 2hPP levels compared to the baseline level during the study were not significant between the two groups.
Conclusion: The insulin glargine regime is effective in reducing HbA1C-FBS-2HPP compared to aspart and Novomix, but no significant difference was seen between the two mentioned regimes. It is recommended to observe more effectiveness and achieve more efficient and reliable results of the studies.

Keywords: Insulin aspart, Insulin Glargine, Glycemic control, Diabetes mellitus, type 2.

Full-Text [PDF 465 kb] (136 Downloads)

Type of Study: Research | Subject: Special
Received: 2024/03/20 | Accepted: 2024/06/9 | Published: 2024/08/20

References

1. Khashayar P, Shirzad N, Zarbini A, Esteghamati A, Hemmatabadi M, Sharafi E. Diabetes-related distress and its association with the complications of diabetes in Iran. Journal of Diabetes & Metabolic Disorders. 2022;21(2):1569-75. [DOI:10.1007/s40200-022-01103-2]

2. Jia W, Xiao X, Ji Q, Ahn KJ, Chuang LM, Bao Y, et al. Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial. The Lancet Diabetes & Endocrinology. 2015;3(4):254-62. [DOI:10.1016/S2213-8587(15)00041-8]

3. Sun Y, Shao L, Niu X, Liu Y, Ge J, Jiang H, et al. Clinical effectiveness of Novolin® 30R versus Lantus® combined with Glucobay® treatment in elderly patients with type 2 diabetes mellitus controlled by oral hypoglycaemic agents: a randomized study. Journal of international medical research. 2014;42(4):993-1001. [DOI:10.1177/0300060514529555]

4. Azami G, Lam SK, Shariff-Ghazali S, Said SM, Aazami S, Mozafari M. Predictors of diabetes self-management behaviors in type 2 diabetes patients. Iranian journal of diabetes and obesity. 2020, 12(4): 192-202. [DOI:10.18502/ijdo.v12i4.5180]

5. Ghadiri-Anari A, Namiranian N, Razavi R, Ashkezari SJ, Mozafari Z, Ordooei M. The Satisfaction level with Insulin Treatment in Type 1 Diabetics-Yazd Diabetes Research Center 2019. Iranian journal of diabetes and obesity. 2023, 15(2): 81-6. [DOI:10.18502/ijdo.v15i2.12965]

6. Liu J, Jiang X, Xu B, Wang G, Cui N, Zhang X, et al. Efficacy and safety of basal insulin-based treatment versus twice-daily premixed insulin after short-term intensive insulin therapy in patients with type 2 diabetes mellitus in China: study protocol for a randomized controlled trial (BEYOND V). Advances in Therapy. 2020;37:1675-87. [DOI:10.1007/s12325-020-01265-6]

7. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Spectrum. 2012;25(3):154-71. [DOI:10.2337/diaspect.25.3.154]

8. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England journal of medicine. 1993;329(14):977-86. [DOI:10.1056/NEJM199309303291401]

9. Bahram ME, Afroundeh R, Pourvaghar MJ, Skishahr FS, Katebi L, Isik O. The Effect of Combined Exercises and Consumption of Mulberry Leaf Extract on Serum Inflammatory Markers Level in Elderly Type 2 Diabetes Mellitus Men. Iranian journal of diabetes and obesity. 2023, 15(3): 129-138. [DOI:10.18502/ijdo.v15i3.13733]

10. Entezari Z, Injinari N, Vakili M, Namiranian N. Identification of Factors Related to Sexual Dysfunction in Type 2 Diabetic Women. Iranian journal of diabetes and obesity. 2023, 15(2): 66-72. [DOI:10.18502/ijdo.v15i2.12963]

11. Reusch JE, Manson JE. Management of type 2 diabetes in 2017: getting to goal. Jama. 2017;317(10):1015-6. [DOI:10.1001/jama.2017.0241]

12. Iafusco D. Insulin therapy regimens in paediatric age. Acta Biomed. 2005 Jan 1;76(Suppl 3):39-43.

13. Sheldon B, Russell‐Jones D, Wright J. Insulin analogues: an example of applied medical science. Diabetes, Obesity and Metabolism. 2009;11(1):5-19. [DOI:10.1111/j.1463-1326.2008.01015.x]

14. Liebl A. Challenges in optimal metabolic control of diabetes. Diabetes/metabolism research and reviews. 2002;18(S3):S36-41. [DOI:10.1002/dmrr.286]

15. Dündar BN, Dündar N, Eren E. Comparison of the efficacy and safety of insulin glargine and insulin detemir with NPH insulin in children and adolescents with type 1 diabetes mellitus receiving intensive insulin therapy. Journal of clinical research in pediatric endocrinology. 2009;1(4):181. [DOI:10.4274/jcrpe.v1i4.56]

16. Jovanovič L, Peters AL, Jiang HH, Hardin DS. Durability of glycemic control with insulin lispro mix 75/25 versus insulin glargine for older patients with type 2 diabetes. Aging Clinical and Experimental Research. 2014 Apr;26:115-21. [DOI:10.1007/s40520-013-0140-8]